Travere Therapeutics Hits New 52-Week High of $66.36, Up 803.85%

Travere Therapeutics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 66.36 on August 21, 2026. This achievement marks a remarkable increase from its 52-week low of USD 17.05, showcasing an impressive one-year performance of 803.85%. In comparison, the S&P 500 has seen a much more modest gain of 20.47% over the same period. As a small-cap company in the Pharmaceuticals & Biotechnology sector, Travere Therapeutics has a market capitalization of USD 2,514 million. Despite its recent stock performance, the company remains in a loss-making position, reflected by its negative price-to-earnings ratio and a return on equity of -43.77%. The company's debt-to-equity ratio stands at -0.05, indicating a unique financial structure. With no dividend yield reported, Travere Therapeutics continues to focus on its growth trajectory within the competitive pharmaceutical landscape. The recent stock activity highlights the company's evolving market position and the potential for further developments in the future.